Cetera Advisor Networks’s Pacira BioSciences PCRX Stock Holding History

Cetera Advisor Networks’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4,950	Closed	-$224K	–	1225
2019 Q4	$224K	Sell	4,950 -2,000	-29%	-$84.9K	0.01%	1104
2019 Q3	$264K	Hold	6,950	–	–	0.01%	977
2019 Q2	$301K	Buy	+6,950	New	+$295K	0.01%	908

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Cetera Advisor Networks's PCRX Position: Q1 2020 in Review

Cetera Advisor Networks sold out of Pacira BioSciences (PCRX) in Q1 2020, closing a stake of 4,950 shares — an estimated $224K sold.

Cetera Advisor Networks first reported a position in PCRX in Q2 2019 and held it in 3 quarters. The position peaked at $301K in Q2 2019. 226 funds tracked by Wall St. Rank hold PCRX as of Q1 2020.

Cetera Advisor Networks reported no remaining Pacira BioSciences position as of Q1 2020 after selling out during the quarter.
Cetera Advisor Networks sold 4,950 Pacira BioSciences shares in Q1 2020, an estimated $224K.
Cetera Advisor Networks first reported a position in Pacira BioSciences in Q2 2019 and held it in 3 quarters.
Cetera Advisor Networks's Pacira BioSciences position peaked at $301K in Q2 2019.
226 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2020.

Based on Cetera Advisor Networks's 13F filing for Q1 2020, filed 8 May 2020.